BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 4, 2008
View Archived Issues
Pfizer to Pay Medivation $225M Up Front in Dimebon Deal
Drugmaker Pfizer Inc. will pay a hefty $225 million up front to Medivation Inc. in a deal to co-develop and market Dimebon, the biotech company's experimental drug for Alzheimer's and Huntington's disease. (BioWorld Today)
Read More
More Government Funding: SIGA Adds $55M, Emergent Gets $24M
Read More
BIO Sets Sights on 2009 for FOBs, Patent Reform
Read More
NewCo News: Wintherix Uses Pfizer Library to Find Wnt Inhibitors for Cancer
Read More
Osprey Raises $11M to Move Kidney Drug into the Clinic
Read More
Other News To Note
Read More
Clinic Roundup
Read More